SkinHealth Q2 Sales Drop 7.8%, Guides Q3 EBITDA to $5–$7M Amid Turnaround
SKIN sits 23% above its 52-week low of $0.551 on light trading volume (0.3× avg).
Summary
SkinHealth Systems posted a 7.8% sales decline in Q2 2026 but improved adjusted EBITDA to $17.0 million. Q3 guidance implies further sequential deterioration, with adjusted EBITDA expected at just $5–$7 million.
Key Events · Earnings and Guidance · SKIN
-
Q2 Sales Decline 7.8%
Net sales fell to $72.1 million from $78.2 million a year ago, with delivery system placements dropping to 770 from 957.
-
Net Loss Swings to $(2.7)M
Q2 2025 included an $18.1 million gain on debt exchange; excluding that, the underlying loss narrowed, and adjusted EBITDA improved to $17.0 million from $13.9 million.
-
Q3 Guidance Implies Steep Sequential Drop
Company guided Q3 net sales to $65–$70 million and adjusted EBITDA to $5–$7 million, down sharply from Q2's $17.0 million, signaling worsening trends.
-
FY2026 Outlook Lowered
Full-year guidance revised to net sales of $280–$290 million and adjusted EBITDA of $39–$46 million, reflecting continued sales pressure.
Analysis · SKIN · Industrial Applications And Services
SkinHealth Systems reported a 7.8% decline in Q2 net sales to $72.1 million, driven by lower delivery system placements (770 vs. 957 a year ago). Net loss was $(2.7) million, swinging from a $19.7 million profit in Q2 2025 that was boosted by a one-time debt exchange gain. Adjusted EBITDA rose to $17.0 million from $13.9 million, reflecting cost discipline and improved gross margins. The company issued Q3 guidance of $65–$70 million in sales and $5–$7 million in adjusted EBITDA, well below the Q2 run rate, signaling continued headwinds. Against a backdrop of a pending reverse stock split to avoid Nasdaq delisting and a $353 million note maturity in October 2026, the results show a business stabilizing profitability but still shrinking — a mixed picture for a company fighting to regain compliance and manage its debt load.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1668 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKIN was trading at $0.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $99.9M. The 52-week trading range was $0.55 to $2.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.